Abstracts tagged "Systemic sclerosis"

Abstract Number: 1067 • 2019 ACR/ARP Annual Meeting
Identification of miRNAs in Systemic Sclerosis Based on Activity and Network Analysis
Yiwei Yuan¹, Yue Wang ², Patricia Pioli ³ and Michael Whitfield ⁴, ¹Geisel School of Medicine at Dartmouth, Hanover, ²Geisel School of Medicine at Dartmouth, Hanover, NH, ³Dartmouth College, Hanover, ⁴Geisel School of Medicine at Dartmouth College, Biomedical Data Science at Dartmouth College, Hanover
Background/Purpose: Systemic sclerosis (SSc; scleroderma) is a rare, heterogenous autoimmune disease characterized by skin fibrosis, vasculopathy and internal organ involvement. SSc patients can be divided…
Abstract Number: 1649 • 2019 ACR/ARP Annual Meeting
Mycophenolate Mofetil and Cyclophosphamide Improve Health-Related Quality of Life in Patients with Systemic Sclerosis Who Participated in SLS II
Elizabeth Volkmann¹, Donald Tashkin ², Michael Roth ³, Holly LeClair ², Philip Clements ², Daniel Furst ⁴, Robert Elashoff ² and Dinesh Khanna ⁵, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of California, Los Angeles, CA, ⁵Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc). The majority of studies investigating novel therapies for…
Abstract Number: 2590 • 2019 ACR/ARP Annual Meeting
Computer Vision Applied to Dual Energy Computed Tomography Images for Precise Calcinosis Cutis Quantification in Patients with Systemic Sclerosis
Anita Chandrasekaran¹, Imran Omar ², Zhicheng Fu ³, Shangping Ren ³ and Monique Hinchcliff ¹, ¹Yale University, Section of Rheumatology, Allergy and Immunology, New Haven, CT, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³San Diego State University, Department of Computer Science, San Diego, CA
Background/Purpose: Calcinosis cutis, found in both systemic sclerosis (SSc) and juvenile dermatomyositis patients, can be extensive and debilitating. Potential treatments have been identified, but a…
Abstract Number: 2611 • 2019 ACR/ARP Annual Meeting
Mesenchymal Stem Cells in Scleroderma: A Systematic Review
Rossana Mejia-Romero ¹, Natalia Aguilera², Juan Pablo Alzate-Granados ³, C Escobar -Soto ⁴, Claudia Mendoza-Pinto ⁵, Mario García-Carrasco ⁵ and Adriana Rojas-Villarraga ⁶, ¹Center for Arthritis and Rehabilitation (CAYRE IPS) ,University of Barcolena, Bogotá, Distrito Capital de Bogota, Colombia, ²Fundacion Universitaria de Ciencias de La Salud-FUCS, Bogotá, Distrito Capital de Bogota, Colombia, ³Fundacion Universitaria de Ciencias de La Salud-FUCS, Bogota, Distrito Capital de Bogota, Colombia, ⁴TRUSTEM, Bogotá, Distrito Capital de Bogota, Colombia, ⁵Systemic Autoimmune Diseases Research Unit, Hospital de Especialidades, UMAE CMNMAC - CIBIOR, Instituto Mexicano del Seguro Social. Department of Rheumatology and Immunology, Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico, ⁶Fundacion Universitaria de Ciencias de La Salud-FUCS. Hospital Infantil Universitario San José., Bogotá, Distrito Capital de Bogota, Colombia
Background/Purpose: Scleroderma (systemic scleroderma or systemic sclerosis, SSc), is a highly heterogeneous autoimmune disease of unknown etiology, with a high rate of therapeutic failure and…
Abstract Number: 720 • 2019 ACR/ARP Annual Meeting
Baseline Subject Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Robert Spiera¹, Nancy Dgetluck ², Bradley Bloom ², Barbara White ² and Christopher Denton ³, ¹Hospital for Special Surgery, New York, NY, ²Corbus Pharmaceuticals, Norwood, MA, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: We report the baseline characteristics of a large cohort of diffuse cutaneous systemic sclerosis (dcSSc) patients enrolled in a Phase 3 trial of lenabasum,…
Abstract Number: 867 • 2019 ACR/ARP Annual Meeting
Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial
Mark Nicolls¹, David Badesch ², Lorinda Chung ³, Robyn Domsic ⁴, Thomas Medsger ⁵, Ashley Pinckney ⁶, Lynette Keyes-Elstein ⁶, Carla D'Aveta ⁶, Meagan Spychala ⁶, R James White ⁷, Paul Hassoun ⁸, Fernando Torres ⁹, Jerry Molitor ¹⁰, Dinesh Khanna ¹¹, Holden Maeker ¹², Beverly Welch ¹³, Ellen Goldmuntz ¹⁴, Roham Zamanian ¹ and -- On Behalf of ASC01 Investigators ¹⁵, ¹Stanford University, Stanford, ²University of Colorado, Denver, ³Stanford University, Palo Alto, CA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, ⁶Rho Federal Systems, Durham, ⁷University of Rochester, Rochester, NY, ⁸Johns Hopkins School of Medicine, Baltimore, ⁹UT Southwestern, Dallas, ¹⁰University of Minnesota, University of Minnesota, ¹¹Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, ¹²Stanford, Stanford, ¹³National Institute of Allergy and Infectious Diseases, NIH, Bethesda, ¹⁴NIAID, Washingto, DC, ¹⁵---, USA
Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc). Pre-clinical and clinical data have strongly implicated immune dysregulation and B cell…
Abstract Number: 1068 • 2019 ACR/ARP Annual Meeting
Classical Monocytes from African Ancestry Patients with Systemic Sclerosis Show Transcription and Energy Regulation Gene Expression Signatures
Paula Ramos¹, Willian da Silveira ², Jena Wirth ¹, Nathan Wilson ¹, Robert Wilson ¹, Jin Hyun Nam ¹, E. Starr Hazard ¹, Jim Oates ³, Melissa Cunningham ¹, Dongjun Chung ¹ and Gary Hardiman ², ¹Medical University of South Carolina, Charleston, ²Queen’s University, Belfast, United Kingdom, ³Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disorder characterized by immune dysregulation, cutaneous and visceral fibrosis, and vasculopathy. It disproportionately affects African ancestry (AA)…
Abstract Number: 1651 • 2019 ACR/ARP Annual Meeting
Multicenter Double-Blind, Proof-of-Concept, Randomized Placebo-Controlled Trial of Riociguat in Systemic Sclerosis-associated Digital Ulcers
Vivek Nagaraja¹, Cathie Spino ¹, Pei-Suen Tsou ¹, Robyn Domsic ², Robert Lafyatis ², Tracy Frech ³, Jessica Gordon ⁴, Virginia Steen ⁵ and Dinesh Khanna ⁶, ¹University of Michigan, Ann Arbor, MI, ²University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ⁴Hospital for Special Surgery, New York, NY, ⁵Georgetown University, Washington, D.C., USA, Georgetown, ⁶Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor
Background/Purpose: The soluble guanylate cyclase stimulator riociguat (RIO) is a vasodilator with efficacy in patients with pulmonary arterial hypertension associated with connective tissue disease. Our…
Abstract Number: 2592 • 2019 ACR/ARP Annual Meeting
Longitudinal Changes in Health-related Quality of Life in Systemic Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplant Compared to Standard of Care
Nancy Maltez¹, Mathieu Puyade ², Pauline Lansiaux ³, Mianbo Wang ⁴, Murray Baron ⁵, Ines Colmegna ⁶, Dominique Farge ⁷ and Marie Hudson ⁸, ¹The Ottawa Hospital, Ottawa, ²CHU de Poitiers Unité d'Hospitalisation d'Aval, Poitiers Cédex, France, ³Institut de Recherche Saint-Louis, Paris, France, ⁴Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada, ⁵Jewish General Hospital, McGill University, Montreal, Canada, ⁶McGill University Health Center, Montreal, QC, Canada, ⁷Hôpital Saint-Louis, AP-HP Assistance Publique des Hôpitaux de Paris, Centre de Référence des Maladies Auto-Immunes Systémiques Rares d’Ile-de-France, Filière ‘FAI2R’, Unité de Médecine Interne: Maladies Auto-immunes et Pathologie Vasculaire (UF 04), Université de Paris, EA 3518, Paris, France; Department of Medicine, McGill University, Montreal, QC, Canada, Paris, France, ⁸Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: In severe, early progressive systemic sclerosis (SSc), autologous hematopoietic stem cell transplantation (AHSCT) allows significant improvements in overall and event free survival. The objectives…
Abstract Number: 2612 • 2019 ACR/ARP Annual Meeting
Minocycline for Refractory Calcinosis in Systemic Sclerosis: A Single-Centre Observational Cohort Study
Carmen Fonseca¹, Voon Ong ² and Christopher Denton ³, ¹UCL Medical School, Royal Free Campus, London, United Kingdom, ²UCL Medical School, Royal Free Campus, London, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: Calcinosis represents a major challenge for patients with systemic sclerosis (SSc) for which there is no standard therapy. Minocycline has been proposed for treatment…
Abstract Number: 723 • 2019 ACR/ARP Annual Meeting
Diagnosis of Systemic Sclerosis: How and When
Cristina Sobrino¹ and Carlos De la Puente ², ¹Rheumatology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ²Hospital Universitario Ramon y Cajal, Madrid, Spain
Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous disease regarding its clinical expression, evolution and forms of presentation. In spite of the lack of a disease…
Abstract Number: 961 • 2019 ACR/ARP Annual Meeting
Microenvironment in Systemic Sclerosis Provides a Protective Niche for Tissue-resident B Cells During B Cell Depletion Therapy with Anti-CD20 Antibody
Ai Kuzumi¹, Ayumi Yoshizaki ¹, Takemichi Fukasawa ¹, Satoshi Ebata ¹, Yoshihide Asano ¹ and Shinichi Sato ¹, ¹University of Tokyo Graduate School of Medicine, Department of Dermatology, Tokyo, Japan
Background/Purpose: B cell depletion therapy with anti-CD20 antibody rituximab has emerged as a potential treatment for systemic sclerosis (SSc). Rituximab, which has been used to…
Abstract Number: 1069 • 2019 ACR/ARP Annual Meeting
CD4+ T Helper Cell Populations with High PD-1 Expression Are Expanded in Systemic Sclerosis
Alisa Mueller¹, Andrea Fava ², Deepak Rao ¹ and Francesco Boin ³, ¹Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³UCSF, San Francisco, CA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by tissue fibrosis, vascular injury, and autoantibody production. CXCR5+ PD-1+ T follicular helper (Tfh) cells, which…
Abstract Number: 1652 • 2019 ACR/ARP Annual Meeting
Anticentromere Antibody Levels and Isotypes Associate with Disease Severity in Systemic Sclerosis
Nina van Leeuwen¹, Jaap Bakker ¹, Annette Grummels ¹, Corrie Wortel ¹, Suzana Jordan ², Oliver Distler ³, Håvard Fretheim ⁴, Anna Maria Hoffmann-Vold ⁵, Hans Ulrich Scherer ⁶, René Toes ¹, Thomas Huizinga ¹ and Jeska de Vries-Bouwstra ¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ³Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁴University Hospital Oslo, Oslo, Norway, ⁵Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁶Leiden University Medical Center, Department of Rheumatology, Leiden, Netherlands
Background/Purpose: Although some studies suggest a possible association between clinical characteristics and isotypes of anticentromere antibodies (ACA) in patients with systemic sclerosis (SSc), characteristics of…
Abstract Number: 2593 • 2019 ACR/ARP Annual Meeting
Cyclophosphamide for the Treatment of Skin Fibrosis in Systemic Sclerosis: A Systematic Review
Marie Hudson ¹, Nancy Maltez², Catherine Ivory ² and Melissa Demery-Varin ³, ¹Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ²The Ottawa Hospital, Ottawa, ³University of Ottawa, Ottawa
Background/Purpose: Systemic sclerosis (SSc) is a chronic disease characterized by multi-organ involvement. Excess collagen deposition and fibrosis is thought to result from a complex interplay…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].